Yousif Capital Management LLC Decreases Stock Holdings in AbbVie Inc. $ABBV

Yousif Capital Management LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 222,486 shares of the company’s stock after selling 8,800 shares during the period. AbbVie comprises approximately 0.5% of Yousif Capital Management LLC’s portfolio, making the stock its 18th largest position. Yousif Capital Management LLC’s holdings in AbbVie were worth $47,621,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Chelsea Counsel Co. purchased a new stake in AbbVie in the third quarter valued at $26,000. Westend Capital Management LLC purchased a new stake in AbbVie in the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new stake in AbbVie in the third quarter valued at $31,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the second quarter valued at $26,000. Finally, Caitlin John LLC purchased a new stake in AbbVie in the third quarter valued at $33,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ABBV shares. Barclays started coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Citigroup reduced their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.25% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New dermatology data for Skyrizi (risankizumab) and Rinvoq (upadacitinib) presented at the AAD strengthen AbbVie’s immunology/dematology growth story — includes long‑term safety, QoL outcomes and FDA label updates for Skyrizi (scalp/genital psoriasis) plus early Phase 3 vitiligo/alopecia signals that could expand indications and market share. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst optimism: JPMorgan calls the recent pullback a buying opportunity and maintains a $260 price target, signaling conviction that longer-term growth (Skyrizi/Rinvoq) and valuation upside remain intact. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target
• Positive Sentiment: Some investors view the company’s recent guidance cut and one‑time R&D charge as noise; bullish commentary reiterates buy ratings based on durable cash flow, strong pipeline, and dividend profile. AbbVie: Lowered Guidance Is Just Noise – Reiterate Buy
• Positive Sentiment: Dividend track record continues to support income investors — articles highlighting AbbVie as a reliable high-yield name add to investor confidence. This Pharma Dividend Has Been Raised Every Single Year for Over a Decade
• Neutral Sentiment: Ongoing observational Parkinson’s study in Belgium is being tracked for real‑world effectiveness signals; data could inform future label/market opportunities but isn’t an immediate revenue driver. AbbVie’s Real‑World Parkinson’s Study in Belgium: What Investors Should Watch
• Negative Sentiment: Pricing risk: AbbVie listed Humira on the TrumpRx platform with a steep (~86%) discount — a politically driven pricing move that could pressure Humira revenue and raises questions about U.S. pricing strategy for legacy brands. This is a material headline given Humira’s past revenue contribution. Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
• Negative Sentiment: Guidance and one‑time charges: AbbVie lowered Q1 and FY‑2026 outlook after taking a $744M R&D charge; that prompted near‑term earnings uncertainty and contributed to the recent share pullback. AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $206.21 on Wednesday. The company has a 50-day simple moving average of $220.95 and a 200-day simple moving average of $224.28. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The stock has a market capitalization of $364.61 billion, a price-to-earnings ratio of 87.38, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the prior year, the company earned $2.16 earnings per share. The business’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.